Company Overview and News

3
DBD / Diebold, Inc. / ATLANTIC INVESTMENT MANAGEMENT INC - DIEBOLD AMENDMENT NO. 6 (Activist Investment)

2018-06-29 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D
DBD

3
DBD / Diebold, Inc. / ATLANTIC INVESTMENT MANAGEMENT INC - DIEBOLD AMENDMENT NO. 6 (Activist Investment)

2018-06-29 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D
DBD

2
DBD / Diebold, Inc. FORM 11-K

2018-06-28 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
DBD

4
DBD / Diebold, Inc. FORM 11-K

2018-06-28 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
DBD

2
Diebold Nixdorf: Opportunity Or Death Spiral?

2018-06-14 seekingalpha
It sounds like the ship is slowly turning around, and the management is still hoping to unlock the $240M in synergy benefits by 2020.
DBD

3
DBD / Diebold, Inc. SD

2018-05-31 sec.gov
Document UNITED STATES
DBD

4
DBD / Diebold, Inc. 8-K (Current Report)

2018-05-23 sec.gov
Document UNITED STATES
DBD

2
DBD / Diebold, Inc. / GAMCO INVESTORS, INC. ET AL - null (Activist Investment)

2018-05-22 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
DBD

4
DBD / Diebold, Inc. / GAMCO INVESTORS, INC. ET AL - null (Activist Investment)

2018-05-22 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
DBD

2
DBD / Diebold, Inc. / GAMCO INVESTORS, INC. ET AL - null (Activist Investment)

2018-05-11 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
DBD

3
DBD / Diebold, Inc. / GAMCO INVESTORS, INC. ET AL - null (Activist Investment)

2018-05-11 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
DBD

51
Hanesbrands, Broadcom Slip into Friday’s 52-Week Low Club

2018-05-04 247wallst
May 4, 2018: Here are four stocks trading with heavy volume among 89 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 2.84 to 1 and on the Nasdaq, advancers led decliners by about 2.5 to 1.
DBD AVGO MNK BRCM HBI

2
DBD / Diebold, Inc. / GAMCO INVESTORS, INC. ET AL - null (Activist Investment)

2018-05-03 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
DBD

3
DBD / Diebold, Inc. / GAMCO INVESTORS, INC. ET AL - null (Activist Investment)

2018-05-03 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
DBD

2
DBD / Diebold, Inc. S-8

2018-05-02 sec.gov
Document As filed with the Securities and Exchange Commission on May 2, 2018
DBD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to DBD / Diebold, Inc. on message board site Silicon Investor.

DBD: oversold at these levels? DOUBLE DAY, INC. (BB: DBDY) BIG GAINS LITTLE RISK
CUSIP: 253651103